Skip to content
DraconiticResearch
Search Sources API
194,230 studies31 sourcesUpdated 44 min ago
Peer-reviewedCC BY-NC-NDBMC anesthesiology

Sevoflurane pretreatment attenuates hypoxia/reoxygenation injury in cardiomyocytes by regulating the GAS6-AS1/miR-483-3p/IGF1 axis.

  • Dan Wu1
  • Dan Yu2
  • Xuesi Guo3
  1. 1Department of Anesthesiology, Zigong Fourth People's Hospital, Zigong, 643000, PR China.
  2. 2Department of Anesthesiology, Hospital of Jilin Provincial Corps, Chinese People's Armed Police Forces, No. 766, Nong'an South Street, Kuancheng District, Changchun, 130052, PR China.
  3. 3Department of Anesthesiology, Hospital of Jilin Provincial Corps, Chinese People's Armed Police Forces, No. 766, Nong'an South Street, Kuancheng District, Changchun, 130052, PR China. [email protected].
Read full textPDFDOICite

Abstract

Background

To investigate the role and mechanism of the lncRNA GAS6-AS1 in sevoflurane (Sev)-mediated cardio-protection against hypoxia/reoxygenation (H/R) injury in cardiomyocytes.Methods

AC16 cardiomyocytes were subjected to H/R injury (6 h hypoxia/24 h reoxygenation) and pretreated with Sev. RT‑qPCR was used to detect the level of GAS6-AS1, miR-483-3p, and IGF1. CCK‑8 and flow cytometry were applied to measure cell proliferation and apoptosis. ELISA determined myocardial injury markers, inflammatory factors, and oxidative stress levels. The targeting relationships were verified by dual‑luciferase reporter and RIP assays.Results

GAS6-AS1 and IGF1 were downregulated, while miR-483-3p was upregulated in H/R‑treated cardiomyocytes. Sev pretreatment upregulated GAS6-AS1 and IGF1, downregulated miR-483-3p, promoted proliferation, inhibited apoptosis, and reduced myocardial damage, inflammation, and oxidative stress. Silencing GAS6-AS1 reversed the cardioprotective effects of Sev. GAS6-AS1 directly targeted miR-483-3p, which in turn directly inhibited IGF1. Inhibiting miR-483-3p restored IGF1 expression and reversed the detrimental effects of GAS6-AS1 silencing.Conclusion

Sev pretreatment protects cardiomyocytes against H/R injury by upregulating the GAS6-AS1/miR-483-3p/IGF1 axis, which offers a novel molecular target for perioperative cardio-protection.Trial registration

Not applicable.

Related

  1. Glycyrrhizic acid attenuates sepsis-induced acute lung injury by regulating macrophage M2 polarization via PRKCD
    Yikun Chen, Yucheng Liu, Jiayi Shen +4
    Journal of thoracic diseasePeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  2. Electroacupuncture pretreatment attenuates myocardial ischemia/reperfusion injury-induced ferroptosis via the p53/SLC7A11/GPX4 pathway
    Jing Mao, Qian-Ru Guo, Yi-Pu Luo +9
    Frontiers in PhysiologyPeer-reviewedCC BY 4.0Full textGeneral medicinePMCEurope PMC
  3. Targeting Mediator Kinase Attenuates Cardiac Hypertrophy by Regulating Enhancer Utilization
    Rachel A. Minerath, Kayla M. Henry, Anna K. Leinheiser +5
    Journal of the American Heart AssociationPeer-reviewedCC BY-NCCardiovascular medicineCrossref
  4. Betaine Attenuates Cuprizone-Induced Cortical Demyelination: The Role of the WNT4/mTOR Signalling Pathway in Regulating Astrogliosis and Synaptic Integrity.
    Yara M Said, Heba-Tallah Abd Elrahim Abd Elkader, Gihad Jamal Bekheet +2
    Journal of biochemical and molecular toxicologyPeer-reviewedCC BY-NC-NDFull textNeurologyEurope PMC
  5. PP–043 Sevoflurane-induced diffuse alveolar hemorrhage: a rare complication of inhalational anesthesia
    Ercan Ayaz, Aynur Gurbanova, Büşra Yağbasan
    BMJ Paediatrics OpenPeer-reviewedCC BYObstetrics, gynaecology & paediatricsDOAJ

Cite

BibTeXRIS
BibTeX
@article{wu2026sevoflurane,
  title = {{Sevoflurane pretreatment attenuates hypoxia/reoxygenation injury in cardiomyocytes by regulating the GAS6-AS1/miR-483-3p/IGF1 axis.}},
  author = {Dan Wu and Dan Yu and Xuesi Guo},
  journal = {BMC anesthesiology},
  year = {2026},
  month = aug,
  doi = {10.1186/s12871-026-04116-z},
  url = {https://europepmc.org/article/MED/42963737},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - Sevoflurane pretreatment attenuates hypoxia/reoxygenation injury in cardiomyocytes by regulating the GAS6-AS1/miR-483-3p/IGF1 axis.
AU  - Dan Wu
AU  - Dan Yu
AU  - Xuesi Guo
PY  - 2026
DA  - 2026/08/11
JO  - BMC anesthesiology
DO  - 10.1186/s12871-026-04116-z
UR  - https://europepmc.org/article/MED/42963737
AB  - Background  To investigate the role and mechanism of the lncRNA GAS6-AS1 in sevoflurane (Sev)-mediated cardio-protection against hypoxia/reoxygenation (H/R) injury in cardiomyocytes.Methods  AC16 cardiomyocytes were subjected to H/R injury (6 h hypoxia/24 h reoxygenation) and pretreated with Sev. RT‑qPCR was used to detect the level of GAS6-AS1, miR-483-3p, and IGF1. CCK‑8 and flow cytometry were applied to measure cell proliferation and apoptosis. ELISA determined myocardial injury markers, inflammatory factors, and oxidative stress levels. The targeting relationships were verified by dual‑luciferase reporter and RIP assays.Results  GAS6-AS1 and IGF1 were downregulated, while miR-483-3p was upregulated in H/R‑treated cardiomyocytes. Sev pretreatment upregulated GAS6-AS1 and IGF1, downregulated miR-483-3p, promoted proliferation, inhibited apoptosis, and reduced myocardial damage, inflammation, and oxidative stress. Silencing GAS6-AS1 reversed the cardioprotective effects of Sev. GAS6-AS1 directly targeted miR-483-3p, which in turn directly inhibited IGF1. Inhibiting miR-483-3p restored IGF1 expression and reversed the detrimental effects of GAS6-AS1 silencing.Conclusion  Sev pretreatment protects cardiomyocytes against H/R injury by upregulating the GAS6-AS1/miR-483-3p/IGF1 axis, which offers a novel molecular target for perioperative cardio-protection.Trial registration  Not applicable.
SN  - 1471-2253
ER  -